Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Real world experience of patient outcomes in a dedicated clonal hematopoiesis hematology clinic

Jayanshu Jain, Julia Cooper, Halle Wade, Marina Beltrami Moreira, James Blachly, Nicole Grieselhuber, Bethany Mundy-Bosse, Uma Borate

Blood (2025) 146 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2025-3167

Published: 2025

Journal Articles

Phase 1b/2 study of axatilimab in combination with azacitidine in advanced Phase MPN, MDS/ MPN overlap and high-risk CMML

Uma Borate, Shivani Handa, Ying Huang, Kaitlyn Dvorak-Kornaus, Nicole Grieselhuber, Alice Mims

Blood (2025) 146 (Supplement 1): 5607.

https://doi.org/10.1182/blood-2025-5607

Published: 2025

Journal Articles

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

Uma Borate, Shivani Handa, Kaitlyn Dvorak-Kornaus, Ronan Swords, Curtis Lachowiez, Qiuhong Zhao, Yazan Madanat

Blood (2025) 146 (Supplement 1): 238.

https://doi.org/10.1182/blood-2025-238

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Guillermo Garcia-Manero, Uma Borate, Andrew Brunner, Bonnie Kiner-Strachan, Bart Scott, Yazan Madanat, Michael Savona, Elizabeth Griffiths, Aram Oganesian, Yuri Sano, Lixia Zhu, Gareth Tomlinson, Danna Chan, Harold Keer, James McCloskey

Blood (2025) 146 (Supplement 1): 491.

https://doi.org/10.1182/blood-2025-491

Published: 2025

Journal Articles

Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia

Justin Watts, Uma Borate, Mark Levis, Yasmin Abaza, Eunice Wang, Joshua Zeidner, Hongliang Cai, Bo Xu, Priya Robson, Akinobu Watanabe, Matthew Hitron, Jatin Shah, Hagop Kantarjian, Naval Daver

Blood (2025) 146 (Supplement 1): 765.

https://doi.org/10.1182/blood-2025-765

Published: 2025

Journal Articles

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Blood (2025) 146 (Supplement 1): 763.

https://doi.org/10.1182/blood-2025-763

Published: 2025

Journal Articles

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2025-3344

Published: 2025

Journal Articles

The bromodomain and extra-terminal domain protein BRD4 promotes both self renewal and inflammation in TET2 mutated clonal hematopoiesis

Blood (2025) 146 (Supplement 1): 1398.

https://doi.org/10.1182/blood-2025-1398

Published: 2025

Journal Articles

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Blood (2025) 146 (Supplement 1): 654.

https://doi.org/10.1182/blood-2025-654

Published: 2025

Journal Articles

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Blood (2025) 146 (Supplement 1): 3432.

https://doi.org/10.1182/blood-2025-3432

Published: 2025

Journal Articles

Preliminary Results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Uma Borate, Jayanshu Jain, Ying Huang, Kaitlyn Dvorak-Kornaus, Alexander Perl, Joshua Zeidner, Alice Mims

Blood (2025) 146 (Supplement 1): 3427.

https://doi.org/10.1182/blood-2025-3427

Published: 2025

Journal Articles

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Pooja Kumar, Deedra Nicolet, Tracelyn Freeman, Lexus Frazier, Allyson Waller, Megan Fleming, Michael Walker, Gregory Behbehani, James Blachly, Uma Borate, Nicole Grieselhuber, Shivani Handa, Jayanshu Jain, Karilyn Larkin, Meixiao Long, Ann-Kathrin Eisfeld, Alice Mims

Blood (2025) 146 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2025-3408

Published: 2025

Journal Articles

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 6.

https://doi.org/10.1182/blood-2025-6

Published: 2025

Journal Articles

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Marie Sebert, Valeria Santini, Uwe Platzbecker, David Valcarcel, Uma Borate, Weishi Yuan, Stephanie Kapsalis, Lorene Simonot, Marissa Panzica, Prapti Patel, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 8254.

https://doi.org/10.1182/blood-2025-8254

Published: 2025

Journal Articles

Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed Acute Myeloid Leukemia with NPM1 mutation or KMT2A rearrangement

Jayanshu Jain, Ying Huang, Kaitlyn Dvorak-Kornaus, Prachi Hirkane, Daniel Corum, Uma Borate

Blood (2025) 146 (Supplement 1): 5211.

https://doi.org/10.1182/blood-2025-5211

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Gabriel Mannis, Nikolai Podoltsev, Deepa Jeyakumar, Justin Watts, Pankit Vachhani, Brian Jonas, Uma Borate, Eric Tam, Harry Erba, Yuling Shi, Donna Haney, William Rice, Rafael Bejar, Naval Daver

Blood (2025) 146 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2025-1645

Published: 2025

Journal Articles

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Eric Huselton, Uma Borate, John Reagan, Richard Little, Steven Gore, Megan Othus, Anna Moseley, Manu Pandey, Xin Wang, Laura Michaelis, Geoffrey Uy, Anjali Advani, Harry Erba

Blood (2025) 146 (Supplement 1): 3466.

https://doi.org/10.1182/blood-2025-3466

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Real world experience of patient outcomes in a dedicated clonal hematopoiesis hematology clinic

Phase 1b/2 study of axatilimab in combination with azacitidine in advanced Phase MPN, MDS/ MPN overlap and high-risk CMML

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

The bromodomain and extra-terminal domain protein BRD4 promotes both self renewal and inflammation in TET2 mutated clonal hematopoiesis

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Preliminary Results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed Acute Myeloid Leukemia with NPM1 mutation or KMT2A rearrangement

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only